The NEO Exchange has welcomed its newest special acquisition company (SPAC) — a real estate investment trust (REIT) focused specifically on the marijuana industry.

Last week, the Subversive Real Estate Acquisition REIT debuted its Class A restricted voting units on the Canadian exchange under the symbol SVX.UN following a US$200 million initial public offering (IPO).


This newest addition is the seventh cannabis-focused acquisition company to list on the NEO and the second to come from New York-based private equity firm Subversive Capital, which launched Subversive Capital Acquisition (NEO:SVC.UN.U) in July last year. Subversive Capital Acquisition’s IPO came in at a whopping US$575 million, making it the largest SPAC IPO in Canadian history, as per a press release.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

SPACs are publicly traded companies that seek capital from investors through an IPO for the purpose of acquiring an existing company. The capital raised through the IPO is put into a trust until the SPAC identifies an acquisition or merger it plans to pursue with the funds. Along with other restrictions, SPACs have a certain period of time — usually 24 months — within which they must complete the acquisition.

Subversive’s REIT was born out of a three way collaboration between Subversive, Canaccord Genuity (TSX:CF) and The Inception Companies, a private equity company that is behind the cannabis-focused Inception REIT.

The Inception Companies is led by CEO Richard Acosta, who said in an interview with the Investing News Network (INN) that the companies came together in November last year and leveraged their shared expertise in the marijuana space to quickly raise the funds for the SPAC.

Acosta noted that the launch of Subversive’s REIT comes at a particularly key point for the cannabis market after a harsh “rerating” of public equities that shook investor sentiment last summer.

“A lot of what resonates with respect to our mandate is we’re out investing in assets at a time when the market is recalibrated,” he said.

The new SPAC REIT aims to have assets across the cannabis supply chain in the US initially, but hopes to focus on the industrial and retail segments of the chain, including cultivation, manufacturing and traditional storefronts.

Acosta added that as time progresses, the sector will see the withdrawal of weaker businesses and the success of firms with strong management teams and balance sheets.

“I think it’s an interesting time to be out evaluating opportunities on this side of that series of events as opposed to before the run up in valuation,” Acosta told INN.

Cannabis sector could see more SPACs moving forward

Now that the marijuana industry is “on the other end of the correction,” Acosta said he expects more cannabis-focused SPACs to begin popping up as an alternative for investors who are interested in the industry, but may not have a specific company in mind.

Jos Schmitt, president and CEO of the NEO Exchange, shared the sentiment, saying that the industry could be introduced to cannabis SPACs dedicated to other parts of the marijuana universe, including research and development and intellectual property.

More broadly, Schmitt said that as an emerging industry in the process of stabilizing, the cannabis space is inviting for acquisition companies, allowing investors to team up with expert players in the market.

When it comes to Subversive’s SPAC REIT, Schmitt noted that the offering is well positioned to be used by companies as a means to get their hands on crucial retail assets.

“You can see that opportunity of companies that are going to shed off some of their capacity,” Schmitt told INN. “Regardless of who the winners are, they’re going to need space and real estate.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

– Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020 inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

Keep reading... Show less

Receipt of licence will be a major milestone in the Company’s commercialization and white-label plans

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“ BevCanna ” or the “ Company ”) is pleased to announce that it has moved to the Final Review Stage for a Standard Processing Licence from Health Canada.

Keep reading... Show less

 Nutritional High International Inc. (CSE: EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company”) is pleased to announce that the Company has completed the proposed conversion of the 10% senior unsecured convertible Debentures (the “10% Debentures”) described in the management information circular dated September 17, 2020.

In accordance with the amendment approved at the meeting of the Debentureholders held on October 8, 2020, approved by the Canadian Securities Exchange, the Company has completed the forced conversion of the 10% Debentures at $.02 per share.

Keep reading... Show less

 Nutritional High International Inc.(CSE: EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company”) announces today that it has made an application to the Ontario Securities Commission to approve a temporary management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), which, if granted, will prohibit trading in securities of the Company by its Chief Executive Officer, Chief Financial Officer and certain other insiders of the Company, whether direct or indirect, so long as the 2020 Filings (as defined below) remain outstanding. The issuance of an MCTO would generally not affect the ability of persons who are not, or who have not been, directors, officers or other insiders of the Company to trade in the Company’s securities.

In discussion with its auditors, the Company has determined that it is not able to meet the November 30, 2020 filing deadline (the “Filing Deadline“) for its audited financial statements for the year ended July 31, 2020, the management’s discussion and analysis and the related CEO and CFO certification relating to the 2020 financial statements (collectively, the “2020 Filings“). Although the audit process is progressing, the auditors anticipate some delays in completing the audit process, such that the Company is not able to meet the Filing Deadline for the 2020 Filings.

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that the Company has entered into a convertible debenture extension and amendment agreement (the “Amending Agreement”) dated October 29, 2020 with Quinsam Capital Corporation (the “Lender”). The Amending Agreement amends certain terms of the 10% convertible debenture dated November 1, 2017 in the principal amount of $262,500 and the 10% convertible debenture dated December 10, 2017 in the principal amount of $237,500, in each case, issued by the Company in favour of the Lender (collectively, the “Convertible Debentures”).

Under the terms of the Amending Agreement, the Lender has agreed to extend the maturity dates of the Convertible Debentures from November 1, 2020 and December 10, 2020, respectively, until April 30, 2021 (the “Amended Maturity Date“). The Amending Agreement also provides that interest on the principal amount outstanding under the Convertible Debentures will be payable by the Company at the originally stated interest rate of 10% per annum until their respective original maturity dates and, thereafter, at the amended interest rate of 12% per annum until the Amended Maturity Date. In addition, the conversion terms of the Convertible Debentures were amended to provide that the outstanding principal owing under the Convertible Debentures may be converted into common shares of the Company at a price of $0.125 per common share instead of $0.15 per common share. All other terms and conditions of the Convertible Debentures remain unchanged. In consideration for the amendments under the Amending Agreement, the Company agreed to pay to the Lender an extension fee of $20,000.

Keep reading... Show less